诊断时的全身免疫标志物可预测晚期乳腺癌的生存获益。
The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer.
作者信息
Nakamoto Shogo, Ikeda Masahiko, Kubo Shinichiro, Yamamoto Mari, Yamashita Tetsumasa, Kuwahara Chihiro
机构信息
Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
出版信息
Cancer Diagn Progn. 2021 Nov 3;1(5):471-478. doi: 10.21873/cdp.10063. eCollection 2021 Nov-Dec.
BACKGROUND/AIM: It has been difficult to establish prognostic markers for overall survival (OS) in patients with advanced breast cancer (ABC). Although systemic immune markers were reported as prognostic markers in several cancers, their utility in ABC remains unclear.
PATIENTS AND METHODS
We retrospectively analyzed 331 ABC patients, who received treatment at Fukuyama City Hospital between April 2009 and December 2020.
RESULTS
Patients with high absolute lymphocyte count (ALC), low neutrophil-to-lymphocyte ratio (NLR), and high lymphocyte-to-monocyte ratio (LMR) had significantly longer OS (p=0.025, p=0.010, and p<0.001, respectively). High ALC and high LMR were independently associated with longer OS (p=0.020 and p=0.015, respectively). High ALC was also independently associated with longer time to treatment failure (p=0.014).
CONCLUSION
These systemic immune markers at diagnosis can predict not only a better OS but also a better TTF after first-line treatment.
背景/目的：在晚期乳腺癌（ABC）患者中，很难建立总生存期（OS）的预后标志物。虽然在几种癌症中，全身免疫标志物被报道为预后标志物，但它们在ABC中的实用性仍不明确。
患者与方法
我们回顾性分析了2009年4月至2020年12月在福山城市医院接受治疗的331例ABC患者。
结果
绝对淋巴细胞计数（ALC）高、中性粒细胞与淋巴细胞比值（NLR）低、淋巴细胞与单核细胞比值（LMR）高的患者总生存期显著更长（分别为p = 0.025、p = 0.010和p < 0.001）。高ALC和高LMR与更长的总生存期独立相关（分别为p = 0.020和p = 0.015）。高ALC还与更长的治疗失败时间独立相关（p = 0.014）。
结论
这些诊断时的全身免疫标志物不仅可以预测更好的总生存期，还可以预测一线治疗后的更好的治疗失败时间（TTF）。
Zotero 插件